These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
325 related articles for article (PubMed ID: 32667982)
1. Adjunctive Daptomycin in the Treatment of Methicillin-susceptible Staphylococcus aureus Bacteremia: A Randomized, Controlled Trial. Cheng MP; Lawandi A; Butler-Laporte G; De l'Étoile-Morel S; Paquette K; Lee TC Clin Infect Dis; 2021 May; 72(9):e196-e203. PubMed ID: 32667982 [TBL] [Abstract][Full Text] [Related]
2. Daptomycin versus placebo as an adjunct to beta-lactam therapy in the treatment of Staphylococcus aureus bacteremia: study protocol for a randomized controlled trial. Cheng MP; Lawandi A; Butler-Laporte G; Paquette K; Lee TC Trials; 2018 May; 19(1):297. PubMed ID: 29843781 [TBL] [Abstract][Full Text] [Related]
3. Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial. Tong SYC; Lye DC; Yahav D; Sud A; Robinson JO; Nelson J; Archuleta S; Roberts MA; Cass A; Paterson DL; Foo H; Paul M; Guy SD; Tramontana AR; Walls GB; McBride S; Bak N; Ghosh N; Rogers BA; Ralph AP; Davies J; Ferguson PE; Dotel R; McKew GL; Gray TJ; Holmes NE; Smith S; Warner MS; Kalimuddin S; Young BE; Runnegar N; Andresen DN; Anagnostou NA; Johnson SA; Chatfield MD; Cheng AC; Fowler VG; Howden BP; Meagher N; Price DJ; van Hal SJ; O'Sullivan MVN; Davis JS; JAMA; 2020 Feb; 323(6):527-537. PubMed ID: 32044943 [TBL] [Abstract][Full Text] [Related]
4. Comparison of outcomes in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia who are treated with β-lactam vs vancomycin empiric therapy: a retrospective cohort study. Wong D; Wong T; Romney M; Leung V BMC Infect Dis; 2016 May; 16():224. PubMed ID: 27215201 [TBL] [Abstract][Full Text] [Related]
5. Clinical Outcomes of Daptomycin Versus Anti-Staphylococcal Beta-Lactams in Definitive Treatment of Methicillin-susceptible Staphylococcus aureus Bloodstream Infections. Agnello S; Wardlow LC; Reed E; Smith JM; Coe K; Day SR Int J Antimicrob Agents; 2021 Aug; 58(2):106363. PubMed ID: 34033912 [TBL] [Abstract][Full Text] [Related]
6. Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. Claeys KC; Zasowski EJ; Casapao AM; Lagnf AM; Nagel JL; Nguyen CT; Hallesy JA; Compton MT; Kaye KS; Levine DP; Davis SL; Rybak MJ Antimicrob Agents Chemother; 2016 Oct; 60(10):5841-8. PubMed ID: 27431221 [TBL] [Abstract][Full Text] [Related]
7. Vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations: study protocol for a phase IIB randomized controlled trial. Kalimuddin S; Phillips R; Gandhi M; de Souza NN; Low JG; Archuleta S; Lye D; Tan TT Trials; 2014 Jun; 15():233. PubMed ID: 24943129 [TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC >1 mg/L: A Multicenter Evaluation. Moise PA; Culshaw DL; Wong-Beringer A; Bensman J; Lamp KC; Smith WJ; Bauer K; Goff DA; Adamson R; Leuthner K; Virata MD; McKinnell JA; Chaudhry SB; Eskandarian R; Lodise T; Reyes K; Zervos MJ Clin Ther; 2016 Jan; 38(1):16-30. PubMed ID: 26585355 [TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of β-lactam versus vancomycin empiric therapy in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. Wong D; Wong T; Romney M; Leung V Ann Clin Microbiol Antimicrob; 2016 Apr; 15():27. PubMed ID: 27112143 [TBL] [Abstract][Full Text] [Related]
10. CAMERA2 - combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial. Tong SY; Nelson J; Paterson DL; Fowler VG; Howden BP; Cheng AC; Chatfield M; Lipman J; Van Hal S; O'Sullivan M; Robinson JO; Yahav D; Lye D; Davis JS; Trials; 2016 Mar; 17():170. PubMed ID: 27029920 [TBL] [Abstract][Full Text] [Related]
11. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. Fowler VG; Boucher HW; Corey GR; Abrutyn E; Karchmer AW; Rupp ME; Levine DP; Chambers HF; Tally FP; Vigliani GA; Cabell CH; Link AS; DeMeyer I; Filler SG; Zervos M; Cook P; Parsonnet J; Bernstein JM; Price CS; Forrest GN; Fätkenheuer G; Gareca M; Rehm SJ; Brodt HR; Tice A; Cosgrove SE; N Engl J Med; 2006 Aug; 355(7):653-65. PubMed ID: 16914701 [TBL] [Abstract][Full Text] [Related]
12. Randomized Multicenter Study Comparing Safety and Efficacy of Daptomycin Versus Standard-of-care in Pediatric Patients With Staphylococcal Bacteremia. Arrieta AC; Bradley JS; Popejoy MW; Bensaci M; Grandhi A; Bokesch P; Glasser C; Du L; Patino H; Kartsonis NA Pediatr Infect Dis J; 2018 Sep; 37(9):893-900. PubMed ID: 29406465 [TBL] [Abstract][Full Text] [Related]
13. Daptomycin Plus Oxacillin for Persistent Methicillin-Susceptible Kufel WD; Zagoria Z; Blaine BE; Steele JM; Mahapatra R; Paolino KM; Thomas SJ Ann Pharmacother; 2024 Apr; 58(4):360-365. PubMed ID: 37542415 [TBL] [Abstract][Full Text] [Related]
14. A randomized phase 2B trial of vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations - results of a prematurely terminated study. Kalimuddin S; Chan YFZ; Phillips R; Ong SP; Archuleta S; Lye DC; Tan TT; Low JGH Trials; 2018 Jun; 19(1):305. PubMed ID: 29859132 [TBL] [Abstract][Full Text] [Related]